Metabolic pathways and chemotherapy drugs

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Chemotherapy drugs are long being used to treat cancer either as single drug or in combination with other treatment strategies. However, the current problem with treatment is the development of chemo-resistance properties of cancer cells that causes relapses at the later stages of the treatment. It is therefore necessary to design and develop new drugs or modify existing treatment strategies. Cancer cells show abnormal cell growth and adopt metabolic pathways that are different from normal cells. There are also links between metabolic pathways and chemo-resistance development in cancer cells. This indicates the importance of integration of knowledge on the metabolic pathways of cancer cells prior to new drug design and development for cancer treatment. In this review, we discuss the metabolic pathways associated with chemo-resistance development and focus on existing or new drugs targeting these pathways.

Original languageEnglish
Title of host publicationFrontiers in Drug Design and Discovery
PublisherBentham Science Publishers B.V.
Pages3-35
Number of pages33
Edition1
DOIs
Publication statusPublished - 1 Jan 2016

Publication series

NameFrontiers in Drug Design and Discovery
Number1
Volume7
ISSN (Print)1574-0889
ISSN (Electronic)2212-1064

Fingerprint

Metabolic Networks and Pathways
Drug Therapy
Pharmaceutical Preparations
Neoplasms
Therapeutics
Drug Design
Drug Delivery Systems
Recurrence
Growth

Keywords

  • Antimetabolites
  • Autophagy
  • Chemoresistance
  • Chemotherapy drugs
  • Drug design and development
  • Metabolic pathways
  • Regulatory proteins
  • Signalling molecules
  • Systems biology

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Rahman, M. (2016). Metabolic pathways and chemotherapy drugs. In Frontiers in Drug Design and Discovery (1 ed., pp. 3-35). (Frontiers in Drug Design and Discovery; Vol. 7, No. 1). Bentham Science Publishers B.V.. https://doi.org/10.2174/9781681081656116070003

Metabolic pathways and chemotherapy drugs. / Rahman, Mahbuba.

Frontiers in Drug Design and Discovery. 1. ed. Bentham Science Publishers B.V., 2016. p. 3-35 (Frontiers in Drug Design and Discovery; Vol. 7, No. 1).

Research output: Chapter in Book/Report/Conference proceedingChapter

Rahman, M 2016, Metabolic pathways and chemotherapy drugs. in Frontiers in Drug Design and Discovery. 1 edn, Frontiers in Drug Design and Discovery, no. 1, vol. 7, Bentham Science Publishers B.V., pp. 3-35. https://doi.org/10.2174/9781681081656116070003
Rahman M. Metabolic pathways and chemotherapy drugs. In Frontiers in Drug Design and Discovery. 1 ed. Bentham Science Publishers B.V. 2016. p. 3-35. (Frontiers in Drug Design and Discovery; 1). https://doi.org/10.2174/9781681081656116070003
Rahman, Mahbuba. / Metabolic pathways and chemotherapy drugs. Frontiers in Drug Design and Discovery. 1. ed. Bentham Science Publishers B.V., 2016. pp. 3-35 (Frontiers in Drug Design and Discovery; 1).
@inbook{28d35f054da640348307f9b9c62554d4,
title = "Metabolic pathways and chemotherapy drugs",
abstract = "Chemotherapy drugs are long being used to treat cancer either as single drug or in combination with other treatment strategies. However, the current problem with treatment is the development of chemo-resistance properties of cancer cells that causes relapses at the later stages of the treatment. It is therefore necessary to design and develop new drugs or modify existing treatment strategies. Cancer cells show abnormal cell growth and adopt metabolic pathways that are different from normal cells. There are also links between metabolic pathways and chemo-resistance development in cancer cells. This indicates the importance of integration of knowledge on the metabolic pathways of cancer cells prior to new drug design and development for cancer treatment. In this review, we discuss the metabolic pathways associated with chemo-resistance development and focus on existing or new drugs targeting these pathways.",
keywords = "Antimetabolites, Autophagy, Chemoresistance, Chemotherapy drugs, Drug design and development, Metabolic pathways, Regulatory proteins, Signalling molecules, Systems biology",
author = "Mahbuba Rahman",
year = "2016",
month = "1",
day = "1",
doi = "10.2174/9781681081656116070003",
language = "English",
series = "Frontiers in Drug Design and Discovery",
publisher = "Bentham Science Publishers B.V.",
number = "1",
pages = "3--35",
booktitle = "Frontiers in Drug Design and Discovery",
address = "Netherlands",
edition = "1",

}

TY - CHAP

T1 - Metabolic pathways and chemotherapy drugs

AU - Rahman, Mahbuba

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Chemotherapy drugs are long being used to treat cancer either as single drug or in combination with other treatment strategies. However, the current problem with treatment is the development of chemo-resistance properties of cancer cells that causes relapses at the later stages of the treatment. It is therefore necessary to design and develop new drugs or modify existing treatment strategies. Cancer cells show abnormal cell growth and adopt metabolic pathways that are different from normal cells. There are also links between metabolic pathways and chemo-resistance development in cancer cells. This indicates the importance of integration of knowledge on the metabolic pathways of cancer cells prior to new drug design and development for cancer treatment. In this review, we discuss the metabolic pathways associated with chemo-resistance development and focus on existing or new drugs targeting these pathways.

AB - Chemotherapy drugs are long being used to treat cancer either as single drug or in combination with other treatment strategies. However, the current problem with treatment is the development of chemo-resistance properties of cancer cells that causes relapses at the later stages of the treatment. It is therefore necessary to design and develop new drugs or modify existing treatment strategies. Cancer cells show abnormal cell growth and adopt metabolic pathways that are different from normal cells. There are also links between metabolic pathways and chemo-resistance development in cancer cells. This indicates the importance of integration of knowledge on the metabolic pathways of cancer cells prior to new drug design and development for cancer treatment. In this review, we discuss the metabolic pathways associated with chemo-resistance development and focus on existing or new drugs targeting these pathways.

KW - Antimetabolites

KW - Autophagy

KW - Chemoresistance

KW - Chemotherapy drugs

KW - Drug design and development

KW - Metabolic pathways

KW - Regulatory proteins

KW - Signalling molecules

KW - Systems biology

UR - http://www.scopus.com/inward/record.url?scp=85054059893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054059893&partnerID=8YFLogxK

U2 - 10.2174/9781681081656116070003

DO - 10.2174/9781681081656116070003

M3 - Chapter

T3 - Frontiers in Drug Design and Discovery

SP - 3

EP - 35

BT - Frontiers in Drug Design and Discovery

PB - Bentham Science Publishers B.V.

ER -